PulmoSIM Therapeutics has announced a strategic partnership with National Jewish Health in Denver, Colorado, and Brown University in Providence, Rhode Island, to bring PT001 into clinical trials for pulmonary arterial hypertension (PAH).

Vivek Gupta, PhD, the scientific founder of PulmoSIM, stated “the great benefit of PT001 is its potential to not only ease symptoms but further halt or reverse the progression of PAH; we are excited to start this clinical-trial collaboration with our partners.”

PT001 is a “drug that targets multiple responsible pathways in PAH to provide curative treatment” according to the company. The drug was recently granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of PAH.

Continue Reading

“We are leveraging VeriSIM Life’s Virtual Drug Development Engine, BIOiSIM, to prioritize the development of PT001, which, unlike currently available therapeutics, has the ability to stop and reverse the progression of PAH,” stated the CEO of PulmoSIM, Jo Varshney, DVM, PhD. According to Dr. Varshney, the partnership will be “applying for the Investigational New Drug Application (IND) very soon.”

Read more about PAH experimental therapies

“I am very excited to be a part of this collaboration to accelerate the development of PT001 toward a curative treatment in the fight against this devastating disorder, which will require the integration and coordination of expertise across multiple fields of study,” said Corey E. Ventetuolo, MD, MS, an associate professor at Brown University and the associate director of the Rhode Island Hospital Pulmonary Hypertension Center in East Providence.

According to the PulmoSIM’s website, BIOiSIM is a “first-in-class artificial intelligence bio-simulation platform developed by VeriSIM Life, to accelerate our drug development by bridging the translational gap between preclinical and clinical phases.”

PulmoSIM Therapeutics was launched in March of this year as a pharmaceutical subsidiary of VeriSIM Life with the goal of addressing the treatment of rare pulmonary diseases including PAH and idiopathic pulmonary fibrosis.

PAH is a chronic, progressive rare disease that is often life-threatening. According to the company’s press release, PAH affects 2 to 5 per million adults. There are currently no disease-modifying therapies available for PAH and lung transplant is the only cure.


PulmoSIM Therapeutics announces strategic partnership with top respiratory hospitals to initiate clinical development of PT001 to treat pulmonary arterial hypertension. PulmoSIM Therapeutics. July 26, 2021.

VeriSIM Life launches PulmoSIM Therapeutics to develop treatments for rare respiratory diseases. VeriSIM Life. March 22, 2021.

PulmoSIM Therapeutics. PulmoSIM Therapeutics. Accessed July 27, 2021.